免疫抑制剂处方与周围动脉疾病患者主要不良心血管及肢体事件的队列研究
该队列研究纳入1506例外周动脉疾病(PAD)患者,其中3.5%被处方免疫抑制剂,中位随访3.9年。调整其他危险因素后,免疫抑制剂处方与主要不良心血管事件(MACE)风险显著升高相关(HR 1.83,95%CI 1.11–3.01;P=0.017),但与主要不良肢体事件(MALE)无显著关联(HR 1.32,95%CI 0.90–1.92;P=0.153)。在慢性肢体威胁性缺血(CLTI)亚组中结果相似。
要点
- PAD患者中免疫抑制剂处方与MACE风险升高独立相关。
- 免疫抑制剂处方与MALE风险无显著关联。
- CLTI亚组中免疫抑制剂与MACE的关联依然显著。
核心结论
- 免疫抑制剂治疗与PAD患者MACE风险升高相关。
研究设计与样本
- 多中心队列研究,纳入1506例间歇性跛行或CLTI患者,其中53例(3.5%)被处方免疫抑制剂,中位随访3.9年。
主要发现
- 调整风险因素后,免疫抑制剂处方与MACE风险显著升高相关(HR 1.83,95%CI 1.11–3.01;P=0.017)。
- 免疫抑制剂处方与MALE风险无显著关联(HR 1.32,95%CI 0.90–1.92;P=0.153)。
- CLTI亚组中,免疫抑制剂与MACE风险升高相关(HR 2.44,95%CI 1.32–4.51;P=0.005),与MALE无显著关联(HR 1.38,95%CI 0.87–2.19;P=0.175),与大截肢无显著关联(HR 1.37,95%CI 0.49–3.86;P=0.547)。
临床怎么用
- 对PAD患者处方免疫抑制剂时,应评估并关注MACE风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Immune activation is strongly implicated in atherosclerotic plaque instability, however, the effect of immunosuppressant drugs on cardiovascular events in patients with peripheral artery disease (PAD) is not known. The aim of this study was to assess whether prescription of one or more immune suppressant drugs was associated with a lower risk of major adverse cardiovascular (MACE; i.e. myocardial infarction, stroke or cardiovascular events) or limb events (MALE; i.e. major amputation or requirement for peripheral revascularization) in patients with PAD. METHODS: A total of 1506 participants with intermittent claudication (n = 872) or chronic limb threatening ischemia (CLTI; n = 634) of whom 53 (3.5%) were prescribed one or more immunosuppressant drugs (prednisolone 41; methotrexate 17; leflunomide 5; hydroxychloroquine 3; azathioprine 2; tocilizumab 2; mycophenolate 1; sulfasalazine 1; adalimumab 1) were recruited from 3 Australian hospitals. Participants were followed for a median of 3.9 (inter-quartile range 1.2, 7.3) years. The association of immunosuppressant drug prescription with MACE or MALE was examined using Cox proportional hazard analyses. RESULTS: After adjusting for other risk factors, prescription of an immunosuppressant drug was associated with a significantly greater risk of MACE (Hazard ratio, HR, 1.83, 95% confidence intervals, CI, 1.11, 3.01; P = 0.017) but not MALE (HR 1.32, 95% CI 0.90, 1.92; P = 0.153). In a sub-analysis restricted to participants with CLTI findings were similar: MACE (HR 2.44, 95% CI 1.32, 4.51; P = 0.005); MALE (HR 1.38, 95% CI 0.87, 2.19; P = 0.175); major amputation (HR 1.37, 95% CI 0.49, 3.86; P = 0.547). CONCLUSIONS: This cohort study suggested that immunosuppressant drug therapy is associated with a greater risk of MACE amongst patients with PAD.
引用
- Golledge J, Velu R, Quigley F, et al. Cohort Study Examining the Association of Immunosuppressant Drug Prescription With Major Adverse Cardiovascular and Limb Events in Patients With Peripheral Artery Disease. Ann Vasc Surg. 2021. PMID: 34537348. doi:10.1016/j.avsg.2021.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。